6-K 1 d395712d6k.htm FORM 6-K Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the month of July, 2017

Commission File Number 001-38079

 

 

UROGEN PHARMA LTD.

(Translation of registrant’s name into English)

 

 

9 Ha’Ta’asiya Street

Ra’anana 4365007, Israel

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F  ☒ Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

On July 19, 2017, UroGen Pharma Ltd. issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form 6-K.

Exhibit

 

99.1    Press Release, dated July 19, 2017: Investigational New Drug Application for RTGelTM in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    UROGEN PHARMA LTD.

July 19, 2017

     By:   /s/ Gary S. Titus
      Gary S. Titus
      Chief Financial Officer